Products & Information Collection of New variant SARS-COV-2 (2019nCOV) -Brazilian variants: P.1 lineage(B.1.1.28.1)

SOCAIL MEDIA

The world is in midst of the COVID-19 pandemic.The SARS-CoV-2 lineage B.1.1.28 has been evolving in Brazil since February 2020. A new lineage, named P.1 (B.1.1.28.1), contains convergent mutations in the spike (S) protein, including several receptor binding domain (spike RBD) mutations E484K, K417T, and N501Y.

Spike Mutation in SARS-COV-2 (2019nCOV)
Brazilian variant P.1 lineage (B.1.1.28.1)
Spike-S1 Subunit
N Terminal
L18F
T20N
P26S
D138Y
R190S
Spike-S1-RBD K417N Important residues mutation
E484K
N501Y
Spike-S1 Subunit C Terminal D614G A popular mutation in different new SARS-CoV-2 lineage
H655Y
Spike-S2 Subunit T1027I
V1176F

GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) P.1 lineage (B.1.1.28.1, Brazilian variant)

Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) P.1 lineage(B.1.1.28.1, Brazilian variant), which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies.

SARS-COV-2 (2019nCOV)-P.1 lineage(B.1.1.28.1, Brazilian variant) of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodiess

GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) - P.1 lineage(B.1.1.28.1, Brazilian variant)

GeneMedi designed a mammalian expression codon-optimized spike mutation/deletion variant vector for COVID-19 SARS-COV-2 (2019nCOV) P.1 lineage(B.1.1.28.1, Brazilian variant)